{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:27:36Z","timestamp":1793165256232,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004168","name":"Universit\u00e4t zu L\u00fcbeck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004168","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Androgen deprivation therapy (ADT) is the mainstay approach for prostate cancer (PCa) management. However, the most commonly used ADT modality, gonadotropin-releasing hormone (GnRH) agonists, has been associated with an increased risk of cardiovascular disease (CVD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The PCa Cardiovascular (PCCV) Expert Network, consisting of multinational urologists, cardiologists and oncologists with expertise in managing PCa, convened to discuss challenges to routine cardiovascular risk assessment in PCa management, as well as how to mitigate such risks in the current treatment landscape.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The experts identified several barriers, including lack of awareness, time constraints, challenges in implementing risk assessment tools and difficulties in establishing multidisciplinary teams that include cardiologists. The experts subsequently provided practical recommendations to improve cardio-oncology care for patients with PCa receiving ADT, such as simplifying cardiovascular risk assessment, individualising treatment based on CVD risk categories, establishing multidisciplinary teams and referral networks and fostering active patient engagement. A streamlined cardiovascular risk-stratification tool and a referral\/management guide were developed for seamless integration into urologists\u2019 practices and presented herein. The PCCV Expert Network agreed that currently available evidence indicates that GnRH antagonists are associated with a lower risk of CVD than that of GnRH agonists and that GnRH antagonists are preferred for patients with PCa and a high CVD risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In summary,\u00a0this article provides insights and guidance to improve management for patients with PCa undergoing ADT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-024-04852-2","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T11:05:26Z","timestamp":1710414326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-3931","authenticated-orcid":false,"given":"Axel S.","family":"Merseburger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Bakshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Chiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Young","family":"Joung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen Yu-Hung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan-Anh","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Fai","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choon Ta","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng Aik","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob See-Tong","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny M.","family":"Rabah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narasimhan","family":"Ragavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Sase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Mui Hian","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry H.","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"issue":"3","key":"4852_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"4852_CR2","unstructured":"World Health Organization, International Agency for Research on Cancer (2020) Cancer tomorrow. https:\/\/gco.iarc.fr\/tomorrow\/en\/dataviz\/isotype?cancers=27&single_unit=50000. Accessed 26 June 2023"},{"key":"4852_CR3","doi-asserted-by":"publisher","first-page":"2976811","DOI":"10.1155\/2022\/2976811","volume":"2022","author":"P Davey","year":"2022","unstructured":"Davey P, Alexandrou K (2022) Assessment and mitigation of cardiovascular risk for prostate cancer patients: a review of the evidence. Int J Clin Pract 2022:2976811. https:\/\/doi.org\/10.1155\/2022\/2976811","journal-title":"Int J Clin Pract"},{"issue":"6","key":"4852_CR4","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/ju.0000000000000714","volume":"203","author":"DP Leong","year":"2020","unstructured":"Leong DP, Fradet V, Shayegan B et al (2020) Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study. J Urol 203(6):1109\u20131116. https:\/\/doi.org\/10.1097\/ju.0000000000000714","journal-title":"J Urol"},{"issue":"13","key":"4852_CR5","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/heartjnl-2022-321888","volume":"109","author":"Z Raisi-Estabragh","year":"2023","unstructured":"Raisi-Estabragh Z, Cooper J, McCracken C et al (2023) Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer. Heart 109(13):1007\u20131015. https:\/\/doi.org\/10.1136\/heartjnl-2022-321888","journal-title":"Heart"},{"issue":"3","key":"4852_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1001\/jama.2018.8359","volume":"320","author":"U. S. Preventive Services Task Force","year":"2018","unstructured":"U. S. Preventive Services Task Force (2018) Risk assessment for cardiovascular disease with nontraditional risk factors: US preventive services task force recommendation statement. JAMA 320(3):272\u2013280. https:\/\/doi.org\/10.1001\/jama.2018.8359","journal-title":"JAMA"},{"key":"4852_CR7","doi-asserted-by":"publisher","first-page":"914875","DOI":"10.3389\/fonc.2022.914875","volume":"12","author":"Y Ye","year":"2022","unstructured":"Ye Y, Zheng Y, Miao Q et al (2022) Causes of death among prostate cancer patients aged 40 years and older in the United States. Front Oncol 12:914875. https:\/\/doi.org\/10.3389\/fonc.2022.914875","journal-title":"Front Oncol"},{"key":"4852_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/rru.S303215","volume":"14","author":"E Choi","year":"2022","unstructured":"Choi E, Buie J, Camacho J et al (2022) Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical providers. Res Rep Urol 14:87\u2013108. https:\/\/doi.org\/10.2147\/rru.S303215","journal-title":"Res Rep Urol"},{"key":"4852_CR9","doi-asserted-by":"publisher","first-page":"100606","DOI":"10.1016\/j.ctarc.2022.100606","volume":"32","author":"L Blas","year":"2022","unstructured":"Blas L, Shiota M, Eto M (2022) Current status and future perspective on the management of metastatic castration-sensitive prostate cancer. Cancer Treat Res Commun 32:100606. https:\/\/doi.org\/10.1016\/j.ctarc.2022.100606","journal-title":"Cancer Treat Res Commun"},{"issue":"6","key":"4852_CR10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.euo.2022.04.007","volume":"5","author":"D Menges","year":"2022","unstructured":"Menges D, Yebyo HG, Sivec-Muniz S et al (2022) Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment. Eur Urol Oncol 5(6):605\u2013616. https:\/\/doi.org\/10.1016\/j.euo.2022.04.007","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"4852_CR11","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1200\/jco.2014.59.1792","volume":"33","author":"S O'Farrell","year":"2015","unstructured":"O\u2019Farrell S, Garmo H, Holmberg L et al (2015) Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 33(11):1243\u20131251. https:\/\/doi.org\/10.1200\/jco.2014.59.1792","journal-title":"J Clin Oncol"},{"issue":"6","key":"4852_CR12","doi-asserted-by":"publisher","first-page":"e0270292","DOI":"10.1371\/journal.pone.0270292","volume":"17","author":"JR Li","year":"2022","unstructured":"Li JR, Wang SS, Chen CS et al (2022) Conventional androgen deprivation therapy is associated with an increased risk of cardiovascular disease in advanced prostate cancer, a nationwide population-based study. PLoS ONE 17(6):e0270292. https:\/\/doi.org\/10.1371\/journal.pone.0270292","journal-title":"PLoS ONE"},{"issue":"1","key":"4852_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/djp404","volume":"102","author":"NL Keating","year":"2010","unstructured":"Keating NL, O\u2019Malley AJ, Freedland SJ et al (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102(1):39\u201346. https:\/\/doi.org\/10.1093\/jnci\/djp404","journal-title":"J Natl Cancer Inst"},{"key":"4852_CR14","unstructured":"US FDA (2010) FDA drug safety communication: update to ongoing safety review of GnRH agonists and notification to manufacturers of GNRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-update-ongoing-safety-review-gnrh-agonists-and-notification. Accessed 1 April 2023"},{"issue":"15","key":"4852_CR15","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1002\/pros.24423","volume":"82","author":"JSK Chan","year":"2022","unstructured":"Chan JSK, Tang P, Hui JMH et al (2022) Association between duration of gonadotrophin-releasing hormone agonist use and cardiovascular risks: a population-based competing-risk analysis. Prostate 82(15):1477\u20131480. https:\/\/doi.org\/10.1002\/pros.24423","journal-title":"Prostate"},{"issue":"3","key":"4852_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","volume":"65","author":"PC Albertsen","year":"2014","unstructured":"Albertsen PC, Klotz L, Tombal B et al (2014) Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 65(3):565\u2013573. https:\/\/doi.org\/10.1016\/j.eururo.2013.10.032","journal-title":"Eur Urol"},{"issue":"1","key":"4852_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.eururo.2020.06.002","volume":"79","author":"M Abufaraj","year":"2021","unstructured":"Abufaraj M, Iwata T, Kimura S et al (2021) Differential impact of gonadotropin-releasing hormone antagonist versus agonist on clinical safety and oncologic outcomes on patients with metastatic prostate cancer: a meta-analysis of randomized controlled trials. Eur Urol 79(1):44\u201353. https:\/\/doi.org\/10.1016\/j.eururo.2020.06.002","journal-title":"Eur Urol"},{"key":"4852_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00555-0","author":"YJ Shao","year":"2022","unstructured":"Shao YJ, Hong JH, Chen CK et al (2022) Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-022-00555-0","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"4852_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00345-020-03433-3","volume":"39","author":"P Davey","year":"2021","unstructured":"Davey P, Kirby MG (2021) Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice. World J Urol 39(2):307\u2013315. https:\/\/doi.org\/10.1007\/s00345-020-03433-3","journal-title":"World J Urol"},{"key":"4852_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2147\/tcrm.S249208","volume":"16","author":"V Perrone","year":"2020","unstructured":"Perrone V, Degli Esposti L, Giacomini E et al (2020) Cardiovascular risk profile in prostate cancer patients treated with GnRH agonists versus antagonists: an Italian real-world analysis. Ther Clin Risk Manag 16:393\u2013401. https:\/\/doi.org\/10.2147\/tcrm.S249208","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"4852_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/bju.15059","volume":"126","author":"EB Cone","year":"2020","unstructured":"Cone EB, Marchese M, Reese SW et al (2020) Lower odds of cardiac events for gonadotrophin-releasing hormone antagonists versus agonists. BJU Int 126(1):9\u201310. https:\/\/doi.org\/10.1111\/bju.15059","journal-title":"BJU Int"},{"issue":"3","key":"4852_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/ehjcvp\/pvab005","volume":"8","author":"F Cirne","year":"2022","unstructured":"Cirne F, Aghel N, Petropoulos JA et al (2022) The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer. Eur Heart J Cardiovasc Pharmacother 8(3):253\u2013262. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab005","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"6","key":"4852_CR23","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1097\/ju.0000000000000384","volume":"202","author":"D Margel","year":"2019","unstructured":"Margel D, Peer A, Ber Y et al (2019) Cardiovascular morbidity in a randomized trial comparing GNRH agonist and GNRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. J Urol 202(6):1199\u20131208. https:\/\/doi.org\/10.1097\/ju.0000000000000384","journal-title":"J Urol"},{"issue":"23","key":"4852_CR24","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","volume":"382","author":"ND Shore","year":"2020","unstructured":"Shore ND, Saad F, Cookson MS et al (2020) Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 382(23):2187\u20132196. https:\/\/doi.org\/10.1056\/NEJMoa2004325","journal-title":"N Engl J Med"},{"key":"4852_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2023.05.011","author":"AJ Nelson","year":"2023","unstructured":"Nelson AJ, Renato LD, Hong H et al (2023) Cardiovascular effects of GnRH antagonists compared with agonists in prostate cancer. JACC Cardiooncol. https:\/\/doi.org\/10.1016\/j.jaccao.2023.05.011","journal-title":"JACC Cardiooncol"},{"issue":"16","key":"4852_CR26","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1161\/circulationaha.121.056810","volume":"144","author":"RD Lopes","year":"2021","unstructured":"Lopes RD, Higano CS, Slovin SF et al (2021) Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation 144(16):1295\u20131307. https:\/\/doi.org\/10.1161\/circulationaha.121.056810","journal-title":"Circulation"},{"issue":"6","key":"4852_CR27","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/j.juro.2010.08.012","volume":"184","author":"MR Smith","year":"2010","unstructured":"Smith MR, Klotz L, Persson BE et al (2010) Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J Urol 184(6):2313\u20132319. https:\/\/doi.org\/10.1016\/j.juro.2010.08.012","journal-title":"J Urol"},{"key":"4852_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkac049","author":"D Merola","year":"2022","unstructured":"Merola D, Schneeweiss S, Sreedhara SK et al (2022) Real-world evidence prediction of a phase IV oncology trial: comparative Degarelix vs. leuprolide safety. JNCI Cancer Spectr. https:\/\/doi.org\/10.1093\/jncics\/pkac049","journal-title":"JNCI Cancer Spectr"},{"issue":"48","key":"4852_CR29","doi-asserted-by":"publisher","first-page":"84572","DOI":"10.18632\/oncotarget.20028","volume":"8","author":"RB Moreira","year":"2017","unstructured":"Moreira RB, Debiasi M, Francini E et al (2017) Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget 8(48):84572\u201384578. https:\/\/doi.org\/10.18632\/oncotarget.20028","journal-title":"Oncotarget"},{"issue":"3","key":"4852_CR30","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","volume":"16","author":"R Iacovelli","year":"2018","unstructured":"Iacovelli R, Ciccarese C, Bria E et al (2018) The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer 16(3):e645\u2013e653. https:\/\/doi.org\/10.1016\/j.clgc.2017.12.007","journal-title":"Clin Genitourin Cancer"},{"issue":"13","key":"4852_CR31","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187\u20131197. https:\/\/doi.org\/10.1056\/NEJMoa1207506","journal-title":"N Engl J Med"},{"issue":"5","key":"4852_CR32","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424\u2013433. https:\/\/doi.org\/10.1056\/NEJMoa1405095","journal-title":"N Engl J Med"},{"issue":"1","key":"4852_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10741-020-09984-2","volume":"27","author":"V Cereda","year":"2022","unstructured":"Cereda V, Falbo PT, Manna G et al (2022) Hormonal prostate cancer therapies and cardiovascular disease: a systematic review. Heart Fail Rev 27(1):119\u2013134. https:\/\/doi.org\/10.1007\/s10741-020-09984-2","journal-title":"Heart Fail Rev"},{"issue":"41","key":"4852_CR34","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229\u20134361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"issue":"8","key":"4852_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11886-021-01561-9","volume":"23","author":"J Boland","year":"2021","unstructured":"Boland J, Choi W, Lee M et al (2021) Cardiovascular toxicity of androgen deprivation therapy. Curr Cardiol Rep 23(8):109. https:\/\/doi.org\/10.1007\/s11886-021-01561-9","journal-title":"Curr Cardiol Rep"},{"key":"4852_CR36","unstructured":"Klotz L (2022) Optimizing the benefit-to-risk ratio of androgen deprivation therapy in prostate cancer. In: The Medical Xchange. Canada: Xfacto Communications"},{"key":"4852_CR37","doi-asserted-by":"publisher","unstructured":"Score Working Group, E. S. C. Cardiovascular Risk Collaboration (2021) SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 42(25):2439\u20132454. https:\/\/doi.org\/10.1093\/eurheartj\/ehab309","DOI":"10.1093\/eurheartj\/ehab309"},{"key":"4852_CR38","doi-asserted-by":"publisher","unstructured":"Score Op Working Group, E. S. C. Cardiovascular Risk Collaboration (2021). SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J 42(25):2455\u20132467. https:\/\/doi.org\/10.1093\/eurheartj\/ehab312","DOI":"10.1093\/eurheartj\/ehab312"},{"key":"4852_CR39","unstructured":"European Society of Cardiology (2023) HeartScore. https:\/\/www.escardio.org\/Education\/Practice-Tools\/CVD-prevention-toolbox\/HeartScore. Accessed 12 April 2023"},{"key":"4852_CR40","unstructured":"University of Nottingham and EMIS (2023) QRISK3. https:\/\/qrisk.org\/. Accessed June 23 2023"},{"key":"4852_CR41","unstructured":"Joint British Societies for the Prevention of Cardiovascular Disease (2023) JBS3 risk score. http:\/\/www.jbs3risk.com\/. Accessed 23 June 2023"},{"key":"4852_CR42","unstructured":"American College of Cardiology (2023) ACC\/AHA CV risk calculator. https:\/\/tools.acc.org\/ascvd-risk-estimator-plus\/#!\/calculate\/estimate\/. Accessed April 12, 2023"},{"issue":"2","key":"4852_CR43","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.36834\/cmej.36848","volume":"9","author":"F Warde","year":"2018","unstructured":"Warde F, Papadakos J, Papadakos T et al (2018) Plain language communication as a priority competency for medical professionals in a globalized world. Can Med Educ J 9(2):e52\u2013e59","journal-title":"Can Med Educ J"},{"issue":"3","key":"4852_CR44","first-page":"4056","volume":"15","author":"CM Zeigler-Johnson","year":"2008","unstructured":"Zeigler-Johnson CM, Rennert H, Mittal RD et al (2008) Evaluation of prostate cancer characteristics in four populations worldwide. Can J Urol 15(3):4056\u20134064","journal-title":"Can J Urol"},{"issue":"6","key":"4852_CR45","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1177\/1557988318798279","volume":"12","author":"HE Taitt","year":"2018","unstructured":"Taitt HE (2018) Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health 12(6):1807\u20131823. https:\/\/doi.org\/10.1177\/1557988318798279","journal-title":"Am J Mens Health"},{"key":"4852_CR46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ijcard.2020.04.080","volume":"317","author":"JC Youn","year":"2020","unstructured":"Youn JC, Chung WB, Ezekowitz JA et al (2020) Cardiovascular disease burden in adult patients with cancer: an 11-year nationwide population-based cohort study. Int J Cardiol 317:167\u2013173. https:\/\/doi.org\/10.1016\/j.ijcard.2020.04.080","journal-title":"Int J Cardiol"},{"issue":"6","key":"4852_CR47","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1200\/jop.2010.000071","volume":"6","author":"LG Gomella","year":"2010","unstructured":"Gomella LG, Lin J, Hoffman-Censits J et al (2010) Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience. J Oncol Pract 6(6):e5\u2013e10. https:\/\/doi.org\/10.1200\/jop.2010.000071","journal-title":"J Oncol Pract"},{"key":"4852_CR48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/jmdh.S117945","volume":"11","author":"T Soukup","year":"2018","unstructured":"Soukup T, Lamb BW, Arora S et al (2018) Successful strategies in implementing a multidisciplinary team working in the care of patients with cancer: an overview and synthesis of the available literature. J Multidiscip Healthc 11:49\u201361. https:\/\/doi.org\/10.2147\/jmdh.S117945","journal-title":"J Multidiscip Healthc"},{"issue":"8","key":"4852_CR49","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s11886-023-01909-3","volume":"25","author":"CT Ng","year":"2023","unstructured":"Ng CT, Bonilla HMG, Bryce AH et al (2023) Approaches to prevent and manage cardiovascular disease in patients receiving therapy for prostate cancer. Curr Cardiol Rep 25(8):889\u2013899. https:\/\/doi.org\/10.1007\/s11886-023-01909-3","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"4852_CR50","doi-asserted-by":"publisher","first-page":"151043","DOI":"10.1016\/j.soncn.2020.151043","volume":"36","author":"L Fleure","year":"2020","unstructured":"Fleure L, Sara S (2020) An exploration of the role of the prostate cancer specialist nurse from two international perspectives. Semin Oncol Nurs 36(4):151043. https:\/\/doi.org\/10.1016\/j.soncn.2020.151043","journal-title":"Semin Oncol Nurs"},{"issue":"10","key":"4852_CR51","first-page":"e608","volume":"62","author":"J Easley","year":"2016","unstructured":"Easley J, Miedema B, Carroll JC et al (2016) Coordination of cancer care between family physicians and cancer specialists: importance of communication. Can Fam Physician 62(10):e608\u2013e615","journal-title":"Can Fam Physician"},{"issue":"12","key":"4852_CR52","doi-asserted-by":"publisher","first-page":"4364","DOI":"10.4103\/jfmpc.jfmpc_514_21","volume":"10","author":"M Seyed-Nezhad","year":"2021","unstructured":"Seyed-Nezhad M, Ahmadi B, Akbari-Sari A (2021) Factors affecting the successful implementation of the referral system: a scoping review. J Family Med Prim Care 10(12):4364\u20134375. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_514_21","journal-title":"J Family Med Prim Care"},{"issue":"2","key":"4852_CR53","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3747\/co.24.3447","volume":"24","author":"J Easley","year":"2017","unstructured":"Easley J, Miedema B, O\u2019Brien MA et al (2017) The role of family physicians in cancer care: perspectives of primary and specialty care providers. Curr Oncol 24(2):75\u201380. https:\/\/doi.org\/10.3747\/co.24.3447","journal-title":"Curr Oncol"},{"issue":"3","key":"4852_CR54","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/annonc\/mdt433","volume":"25","author":"MTE Puts","year":"2014","unstructured":"Puts MTE, Tu HA, Tourangeau A et al (2014) Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review. Ann Oncol 25(3):564\u2013577. https:\/\/doi.org\/10.1093\/annonc\/mdt433","journal-title":"Ann Oncol"},{"key":"4852_CR55","doi-asserted-by":"publisher","first-page":"103727","DOI":"10.1016\/j.ijnurstu.2020.103727","volume":"110","author":"A Rashidi","year":"2020","unstructured":"Rashidi A, Kaistha P, Whitehead L et al (2020) Factors that influence adherence to treatment plans amongst people living with cardiovascular disease: a review of published qualitative research studies. Int J Nurs Stud 110:103727. https:\/\/doi.org\/10.1016\/j.ijnurstu.2020.103727","journal-title":"Int J Nurs Stud"},{"key":"4852_CR56","first-page":"284","volume":"240","author":"AH Krist","year":"2017","unstructured":"Krist AH, Tong ST, Aycock RA et al (2017) Engaging patients in decision-making and behavior change to promote prevention. Stud Health Technol Inform 240:284\u2013302","journal-title":"Stud Health Technol Inform"},{"issue":"8","key":"4852_CR57","doi-asserted-by":"publisher","first-page":"e0220116","DOI":"10.1371\/journal.pone.0220116","volume":"14","author":"S Dineen-Griffin","year":"2019","unstructured":"Dineen-Griffin S, Garcia-Cardenas V, Williams K et al (2019) Helping patients help themselves: a systematic review of self-management support strategies in primary health care practice. PLoS ONE 14(8):e0220116. https:\/\/doi.org\/10.1371\/journal.pone.0220116","journal-title":"PLoS ONE"},{"issue":"5","key":"4852_CR58","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1007\/s00520-021-06753-1","volume":"30","author":"S Pan","year":"2022","unstructured":"Pan S, Mao J, Wang L et al (2022) Patient participation in treatment decision-making of prostate cancer: a qualitative study. Support Care Cancer 30(5):4189\u20134200. https:\/\/doi.org\/10.1007\/s00520-021-06753-1","journal-title":"Support Care Cancer"},{"key":"4852_CR59","doi-asserted-by":"publisher","first-page":"727487","DOI":"10.3389\/fcvm.2022.727487","volume":"9","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang Y, Han X et al (2022) Cardio-oncology: a myriad of relationships between cardiovascular disease and cancer. Front Cardiovasc Med 9:727487. https:\/\/doi.org\/10.3389\/fcvm.2022.727487","journal-title":"Front Cardiovasc Med"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04852-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-04852-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04852-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T16:23:32Z","timestamp":1735835012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-04852-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4852"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-04852-2","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]},"assertion":[{"value":"10 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Axel S. Merseburger\u2013\u2013lectures\/speaker\/honoraria: AstraZeneca, Accord Health, Astellas, Bayer, Bristol-Myers Squibb, Eisai, Ferring, Ipsen, MSD, Merck Serono, Janssen, Takeda, TEVA, Astellas, Novartis, Pfizer, Recordati and Roche; consultant: AstraZeneca, Astellas, Bayer, Bristol-Myers Squibb, Ferring, Ipsen, Janssen, EUSAPharm, MSD, Merck Serono, Novartis, Takeda, Teva, Pfizer, Recordati and Roche; research and clinical trials: AstraZeneca, Astellas, Bayer, Bristol-Myers Squibb, Ipsen, Janssen, EUSAPharm, MSD, Merck Serono, Novartis, Takeda, Teva, Pfizer und Roche. Teng Aik Ong\u2013\u2013research grant: Ferring. Ganesh Bakshi\u2013\u2013nothing to declare. Dong-Yi Chen\u2013\u2013nothing to declare. Edmund Chiong\u2013\u2013lectures\/speaker\/honoraria: Astellas, Janssen, Bayer, AstraZeneca, Ipsen, Amgen, Ferring and Novartis. Michel Jabbour\u2013\u2013nothing to declare. Jae Young Joung\u2013\u2013nothing to declare. Allen Yu-Hung Lai\u2013\u2013an employee of Ferring Pharmaceuticals. Nathan Lawrentschuk\u2013\u2013proctor and speaker: Device Technologies and Getz Healthcare; speaker: Astellas; advisory board: Penthrax. Tuan-Anh Le\u2013\u2013nothing to declare. Chi Fai Ng\u2013\u2013research grant: Astellas, Takeda, Bayer and Ipsen; investigator in studies: Bayer, Astellas and Pfizer; speaker: Janssen. Choon Ta Ng\u2013\u2013lectures\/speaker\/honoraria: AstraZeneca, Ferring and Novartis. Jacob See-Tong Pang\u2013\u2013nothing to declare. Danny M. Rabah\u2013\u2013nothing to declare. Narasimhan Ragavan\u2013\u2013nothing to declare. Kazuhiro Sase\u2013\u2013nothing to declare. Hiroyoshi Suzuki\u2013\u2013research grants: Astellas, Bayer, Janssen and Nihon Kayaku; consulting fees and honoraria: Astellas, AstraZeneca, Bayer, Chugai, Daiichi-Sankyo, Eli-Lily, Janssen, MSD, Roche and Sanofi. Michelle Mui Hian Teo\u2013\u2013an employee of Ferring Pharmaceuticals. Hiroji Uemura\u2013\u2013advisory board: Ferring, Bayer, AstraZeneca, Janssen, Astellas, Takeda and Ono Pharm.; speaker: Sanofi, Pfizer, MSD, Chugai, Nihon Kayaku, Nippon Shinyaku, Kissei and Kyowa-Kirin. Henry H. Woo\u2013\u2013study sponsor: Prodeon; consulting fees: Astellas, Janssen, Mundipharma, Ferring, Medical Developments International and Boston Scientific; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Ferring and Bayer; leadership or fiduciary role in other board, society, committee or advocacy group: Royal Australasian College of Surgeons, Urological Society of Australia and New Zealand, Australasian Urological Foundation and Australian and New Zealand Urogenital and Prostate Trials Group; receipt of equipment, materials, drugs, medical writing, gifts or other services: Prospection Pty Ltd., and Prodeon.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}}],"article-number":"156"}}